Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960671 | 0.86 | ACHE (0.33) | ACHEKDM4EMAPTMAPK1MMP14 | |
| SCHEMBL9960633 | 0.85 | FABP3 (0.36) | ACHEKDM4EMAPTMAPK1MMP14 | |
| SCHEMBL9960685 | 0.73 | PPIA (0.33) | MEN1KMT2AKDM4EMAPTMAPK1 | |
| SCHEMBL9960649 | 0.73 | MYC (0.33) | MEN1KMT2AMAPT | |
| SCHEMBL9960838 | 0.72 | TP53 (0.37) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL9960677 | 0.72 | ELANE (0.34) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL9960041 | 0.72 | MAPT (0.44) | MEN1KMT2AKDM4EMAPTMAPK1 | |
| SCHEMBL9960566 | 0.71 | MYC (0.34) | MEN1KMT2AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL9960591 | 0.71 | KMT2A (0.33) | MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL9961060 | 0.70 | MEN1 (0.42) | MEN1KMT2AKDM4ECDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | claimed |
| US-20130331446-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | US | claimed |
| EP-2655312-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
| US-20130331446-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | US | disclosed |
| EP-2655312-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331446-A1 | 3-ACYL-INGENOLS II | IL33, CXCL8, MMP8 | MEN1 4628/4885KMT2A 4780/4885ACHE 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.